ONLINE APPENDIX
Online Figure 1
Trial Profile. Of all patients who underwent percutaneous coronary intervention with DES
during the study period, 3,224 patients were eligible. A total of 1,811 patients (56%) were
enrolled and randomly assigned to the stent types. Two-year follow-up data was obtained from
1,810 patients (one patient withdrew consent). BMS=bare metal stent. DES=drug-eluting stent
Online Figure 2.
Patient-Reported Chest Pain at 1 and 2-Years (in Patients who Provided Chest Pain
Information at Both Times). Patient-reported chest pain classified into 4 scores: 0= no chest
pain at all; 1= chest pain only during most severe physical exertion; 2= chest pain at moderate
physical effort (during moderate/normal daily activities); 3= chest pain during mild physical
exertion or at rest. Panels A and B provide information about the presence and extent (i.e., pain
score) of chest pain at 1 and 2-year follow-up in 1,572 patients, who were alive at 2-year followup and answered the chest pain questionnaire both times.
Online Table 1. Supplement II. Outcome of patients in whom longitudinal stent deformation had been
observed (all Promus Element stent group).
ACC/AHA
Case
1
Vessel
and
segment
LAD, mid
Lesion
characteristics
lesion
class
bifurcation
RCA,
mid
3
LAD,
prox.
bifurcation
LAD,
prox.
bifurcation
calcification
6
Left
main
bifurcation
RCA,
distal
bifurcation
8
LAD,
prox.
moderate
calcification
9
RCA,
mid
7
–
–
C
2.5 x
32
proximal
+
additional
proximal
stent
–
–
C
3.5 x
24
proximal
+
additional
proximal
stent
–
–
C
2.25 x
16
proximal
–
additional
proximal
stent
–
–
C
2.25 x
22
proximal
+
additional
proximal
stent
–
–
B2
3.5 x
16
proximal
+
–
–
C
2.5 x
32
proximal
+
additional
proximal
stent
+
–
C
3.0 x
12
proximal
+
additional
proximal
stent
–
–
C
3.0 x
24
proximal
+
–
–
lesion
lesion
severe
calcification
2-year
follow-up
additional
proximal
stent
severe
calcification
2-year
followup
+
lesion
LAD,
prox.
Procedural
consequences
proximal
lesion
5
Postdilation of
stent
performed
3.0 x
38
severe
2
size
(mm)
Proximal/
distal
location
in stent
Consecutive
adverse
clinical
events until
C
lesion
4
Stent
DAPT
use at
postdilation
of stent
postdilation
of stent
ACC/AHA=American College of Cardiology/American Heart Association; LAD=left anterior descending
artery; Prox.=proximal; RCA=right coronary artery; DAPT=dual antiplatelet therapy. +=yes; –=no.
Data except results of 2-year follow-up have previously been reported in: von Birgelen C, Sen H, Lam MK, et al.
Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous
coronary intervention (DUTCH PEERS): A randomised, single-blind, multicentre, non-inferiority trial. Lancet
2014;383:413-23.
Outcome of patients in whom longitudinal stent deformation had been observed
(all Promus Element stent group). ACC/AHA=American College of Cardiology/
American Heart Association; LAD=left anterior descending artery; Prox.=proximal;
RCA=right coronary artery; DAPT=dual antiplatelet therapy. + = yes; – = no.
Online Table 2 (Supplement III).
Anticoagulant Use at 1 and 2-Year Follow-up.
Total
Resolute Integrity
ZES
Promus Element
EES
At 1 year
N=1776
N=883
N=883
Ascal
1575 (88.7)
786 (89.0)
789 (88.4)
0.66
P2Y12 inhibitor
437 (24.2)
227 (25.7)
210 (23.5)
0.28
DAPT
1534 (86.4)
765 (86.6)
769 (86.1)
0.75
Vitamin K antagonist
195 (11.0)
90 (10.2)
105 (11.8)
0.29
N=1753
N=872
N=881
Ascal
1523 (86.9)
760 (87.2)
763 (86.6)
0.73
P2Y12 inhibitor
205 (11.7)
102 (11.7)
103 (11.7)
1.00
DAPT
157 (9.0)
78 (8.9)
79 (9.0)
0.99
Vitamin K antagonist
214 (12.2)
98 (11.2)
116 (13.2)
0.22
At 2 years
p value
Values are % (n/N). DAPT= dual-antiplatelet therapy. Analysis based on survivors at 1 and 2-year, respectively.